DiscoverHow the Masters Treat CancerDr. Edgardo Santos' Interview with Toni Choueiri, MD
Dr. Edgardo Santos' Interview with Toni Choueiri, MD

Dr. Edgardo Santos' Interview with Toni Choueiri, MD

Update: 2025-08-25
Share

Description

Interviews withSummit Director Edgardo S. Santos Castillero, MD, FACP, FASCO at NOSCM at 2024 | New Orleans Summer Cancer Meeting

Dr. Edgardo Santos' Interview with Toni Choueiri, MD

Dr. Choueiri highlighted pembrolizumab as the first adjuvant immunotherapy approved for intermediate-high and high-risk kidney cancer—demonstrating overall survival benefits—and confirmed that first-line nivolumab plus ipilimumab improves outcomes, whereas PD-1 rechallenge after progression is unsupported. He also presented HIF-2 inhibitors like belzutifan, which have shown notable progression-free survival gains in phase 3 trials.

Comments 
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Dr. Edgardo Santos' Interview with Toni Choueiri, MD

Dr. Edgardo Santos' Interview with Toni Choueiri, MD

The Medical Educator Consortium